Novo Nordisk A/S Says FDA’s Victoza Feedback Delayed Beyond Year-End

Bookmark and Share

Reuters -- Danish drugmaker Novo Nordisk said on Wednesday that formal feedback from U.S. regulators on its Victoza diabetes drug has been delayed beyond year-end but is expected "within weeks".
MORE ON THIS TOPIC